Who makes Tricagrelor?

Tricagrelor is developed by Mayo Clinic.

What development phase is Tricagrelor in?

Tricagrelor is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Tricagrelor

Mayo Clinic · FDA-approved active Small molecule Quality 1/100

At a glance

Generic name	Tricagrelor
Sponsor	Mayo Clinic
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clopidogrel Monotherapy in Patients With High Bleeding Risk (PHASE4)
Evaluation of Ticagrelor Anti Platelet and Pleiotropic Effects in Patients Undergoing Percutaneous Coronary Intervention for an Acute Coronary Syndrome (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tricagrelor CI brief — competitive landscape report
Tricagrelor updates RSS · CI watch RSS
Mayo Clinic portfolio CI